Weight-related health conditions that support eligibility at BMI 27 to 30: High blood pressure (hypertension) Type 2 diabetes or prediabetes Sleep apnoea (obstructive sleep apnoea) Cardiovascular disease (heart attack, stroke, heart failure) Dyslipidaemia (high cholesterol or triglycerides) Non-alcoholic fatty liver disease (NAFLD) Polycystic ovary syndrome (PCOS) with metabolic features Osteoarthritis affecting weight-bearing joints Absolute contraindications mean Mounjaro is not safe to prescribe regardless of weight: Personal or family history of medullary thyroid carcinoma (MTC) Multiple endocrine neoplasia syndrome type 2 (MEN-2) Hypersensitivity to tirzepatide or any excipient Pregnancy or active attempt to conceive Breastfeeding Relative contraindications require careful assessment and may rule out treatment: History of pancreatitis Severe gastrointestinal disease including gastroparesis Diabetic retinopathy with recent worsening Severe kidney impairment (CKD stage 4 to 5) Severe liver disease Active eating disorder including bulimia nervosa History of suicidal ideation or active mental health crisis Type 1 diabetes (Mounjaro is licensed for type 2 only) Specific medication interactions require dose review: Oral contraceptive pills may have reduced effectiveness during dose escalation Insulin and sulphonylureas require dose adjustment when combined with Mounjaro Warfarin requires INR monitoring after starting The eligibility assessment at The Wellness is a structured 30-minute consultation including detailed medical history, medication review, BMI confirmation, blood pressure measurement, and baseline blood tests covering HbA1c, kidney function, liver function, lipid profile, thyroid function, and amylase or lipase
Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite
Icons: fragrance-free, sensitive-friendly, even-tone support
The table below summarizes the core functional differences of these two copper peptides
